For instance, HMG-CoA reductase inhibitors (statins) block EBV-induced mevalonate metabolism and limit outgrowth of EBV-transformed B cells in culture [2,5], suggesting that it would be of interest to test these widely used medications in murine PTLD models. Here, HMGCR is linked to post-transplant lymphoproliferative disease.